within Pharmacolibrary.Drugs.ATC.V;

model V03AE07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 1e-06,
    adminDuration  = 600,
    adminMass      = 667 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AE07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Calcium acetate is an inorganic mineral supplement used primarily to control hyperphosphatemia (elevated blood phosphate levels) in patients with end-stage renal disease (ESRD) undergoing dialysis. It acts as a phosphate binder in the gastrointestinal tract, preventing absorption of dietary phosphate. The drug is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Estimated typical oral pharmacokinetic parameters for adult patients with end-stage renal disease, as no detailed compartmental pharmacokinetic model has been published.</p><h4>References</h4><ol><li><p>Groenendaal-van de Meent, D, et al., &amp; Schaddelee, M (2021). Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals. <i>Clinical therapeutics</i> 43(6) 1079–1091. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2021.03.025\">10.1016/j.clinthera.2021.03.025</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33962762/\">https://pubmed.ncbi.nlm.nih.gov/33962762</a></p></li><li><p>Kays, MB, et al., &amp; Sowinski, KM (2003). Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. <i>American journal of kidney diseases : the official journal of the National Kidney Foundation</i> 42(6) 1253–1259. DOI:<a href=\"https://doi.org/10.1053/j.ajkd.2003.08.027\">10.1053/j.ajkd.2003.08.027</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14655198/\">https://pubmed.ncbi.nlm.nih.gov/14655198</a></p></li><li><p>Cai, J, et al., &amp; Weaver, CM (2004). Calcium bioavailability and kinetics of calcium ascorbate and calcium acetate in rats. <i>Experimental biology and medicine (Maywood, N.J.)</i> 229(1) 40–45. DOI:<a href=\"https://doi.org/10.1177/153537020422900105\">10.1177/153537020422900105</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14709775/\">https://pubmed.ncbi.nlm.nih.gov/14709775</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AE07;
